Objective: Cost of Age-Related MAcular degeneration in Italy. The retrospective analysis of the Study CARMA To evaluate the direct costs of patients affected by Age-related Macular Degeneration (AMD) in Italy, from the perspective of the payers. Design and setting: A retrospective study, conducted in seven centers of North and Centre South Italy. 497 patients affected by AMD were enrolled and divided into six subgroups: new and previous drusen, new and previous geographic atrophy, new and previous Choroidal NeoVascularization (CNV). Newly diagnosed subgroups included patients with a diagnosis of AMD made less than 6 months before the enrolment into the study. Main outcome measures and results: The high mean age (74 years) and the high proportion in the sample of retired people (76%) reflected the expected characteristics of patients with AMD. The mean cost per patient by group was: €105,7 and 91,7 for new and previous drusen, €85,4 and €180,9 for new and previous geographic atrophy, €264,3 and €290,1 for new and previous CNV. Conclusions: The study provides some potentially useful information about the costs of AMD in Italy: the analysis did not confirm statistical differences between new and previous diagnosed patients.
Cost of age-related macular degeneration in Italy. The retrospective analysis of the study CARMA / Denti, C; Garattini, L; Lanzetta, P; Parazzini, F; Ricci, E; Parodi, Mb; Pantaleoni, Fb; Camicione, P; Piccolino, Fc; Del Sal, C; Gharbiya, Magda; Menchini, U; Niccoli, M; Pece, A; Pilotto, E; Piermarocchi, S; Saviano, S; Scarpa, G; Virgili, G.. - In: PHARMACOECONOMICS. - ISSN 1170-7690. - 4:2(2002), pp. 57-63.
Cost of age-related macular degeneration in Italy. The retrospective analysis of the study CARMA
Ricci E;GHARBIYA, Magda;
2002
Abstract
Objective: Cost of Age-Related MAcular degeneration in Italy. The retrospective analysis of the Study CARMA To evaluate the direct costs of patients affected by Age-related Macular Degeneration (AMD) in Italy, from the perspective of the payers. Design and setting: A retrospective study, conducted in seven centers of North and Centre South Italy. 497 patients affected by AMD were enrolled and divided into six subgroups: new and previous drusen, new and previous geographic atrophy, new and previous Choroidal NeoVascularization (CNV). Newly diagnosed subgroups included patients with a diagnosis of AMD made less than 6 months before the enrolment into the study. Main outcome measures and results: The high mean age (74 years) and the high proportion in the sample of retired people (76%) reflected the expected characteristics of patients with AMD. The mean cost per patient by group was: €105,7 and 91,7 for new and previous drusen, €85,4 and €180,9 for new and previous geographic atrophy, €264,3 and €290,1 for new and previous CNV. Conclusions: The study provides some potentially useful information about the costs of AMD in Italy: the analysis did not confirm statistical differences between new and previous diagnosed patients.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
